Xentuzumab Uses, Dosage, Side Effects and more
Xentuzumab is under investigation in clinical trial NCT02191891 (Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)).
| Attribute | Details |
|---|---|
| Trade Name | Xentuzumab |
| Generic | Xentuzumab |
| Xentuzumab Other Names | Xentuzumab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
